ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms and Metabolic Pathway of Diabetic Retinopathy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (1 February 2021) | Viewed by 3189

Special Issue Editor


E-Mail
Guest Editor
Korea Institute of Oriental Medicine, Daejeon, Korea
Interests: AGEs formation; reactive oxidative stress; retinal endothelial cells; pericytes

Special Issue Information

Dear Colleagues,

Molecular mechanisms of diabetic retinopathy are suggested to underlie diabetes-induced complications. The pathogenesis of diabetic retinopathy has been shown to be related to increased polyol pathway flux, increased formation of advanced glycation end-products (AGEs), activation of the protein kinase C (PKC) pathway, and increased oxidative stress.

Retinal vascular occlusion causes the upregulation of such factors as insulin-like growth factor (IGF), stromal-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), angiopoietins (Ang-2), tumor necrosis factor (TNF), and basic fibroblast growth factor-2 (bFGF), which eventually contribute to the pathogenesis of diabetic retinopathy. The question of how growth factors play a pivotal role in diabetic retinopathy remains open to discussion.

Although alterations in metabolic pathways are suggested to occur in a hyperglycemic environment, the heightened production of reactive oxygen species (ROS) may interconnect the foregoing pathways. Nevertheless, recent advances in genetic technology have enabled us to show that a significant number of epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNAs, participate in the development and progression of diabetic retinopathy.

This Special Issue of the International Journal of Molecular Science aims to provide an overview of the latest developments in our understanding of the mechanisms of diabetic retinopathy and their use in new therapeutic approaches to the treatment of various stages of diabetic retinopathy.

Dr. Young Sook Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic retinopathy
  • retinal microvascular abnormalities
  • reactive oxygen species
  • vascular cell death
  • vascular occlusion
  • epigenetic alterations.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1776 KiB  
Article
VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients
by Sara Rezzola, Jessica Guerra, Adwaid Manu Krishna Chandran, Alessandra Loda, Anna Cancarini, Piergiuseppe Sacristani, Francesco Semeraro and Marco Presta
Int. J. Mol. Sci. 2021, 22(4), 2179; https://doi.org/10.3390/ijms22042179 - 22 Feb 2021
Cited by 22 | Viewed by 2862
Abstract
Proliferative diabetic retinopathy (PDR), a major complication of diabetes mellitus, results from an inflammation-sustained interplay among endothelial cells, neurons, and glia. Even though anti-vascular endothelial growth factor (VEGF) interventions represent the therapeutic option for PDR, they are only partially efficacious. In PDR, Müller [...] Read more.
Proliferative diabetic retinopathy (PDR), a major complication of diabetes mellitus, results from an inflammation-sustained interplay among endothelial cells, neurons, and glia. Even though anti-vascular endothelial growth factor (VEGF) interventions represent the therapeutic option for PDR, they are only partially efficacious. In PDR, Müller cells undergo reactive gliosis, produce inflammatory cytokines/chemokines, and contribute to scar formation and retinal neovascularization. However, the impact of anti-VEGF interventions on Müller cell activation has not been fully elucidated. Here, we show that treatment of MIO-M1 Müller cells with vitreous obtained from PDR patients stimulates cell proliferation and motility, and activates various intracellular signaling pathways. This leads to cytokine/chemokine upregulation, a response that was not mimicked by treatment with recombinant VEGF nor inhibited by the anti-VEGF drug ranibizumab. In contrast, fibroblast growth factor-2 (FGF2) induced a significant overexpression of various cytokines/chemokines in MIO-M1 cells. In addition, the FGF receptor tyrosine kinase inhibitor BGJ398, the pan-FGF trap NSC12, the heparin-binding protein antagonist N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe Boc2, and the anti-inflammatory hydrocortisone all inhibited Müller cell activation mediated by PDR vitreous. These findings point to a role for various modulators beside VEGF in Müller cell activation and pave the way to the search for novel therapeutic strategies in PDR. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Metabolic Pathway of Diabetic Retinopathy)
Show Figures

Figure 1

Back to TopTop